Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Fractyl Health, Inc. (GUTS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0,56, with a market capitalisation of $97,35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,38 to $2,45. This page covers its latest market performance, valuation, price trends and company information.
$97,35M | |
$0,56 | |
$14,50 | |
$0,38 | |
$0,56 | |
1,66K | |
1,64M | |
-- | |
$2,44 | |
$0,38 | |
-- | |
-- |
Fractyl Health, Inc. (GUTS) is trading at $0,56 in pre-market trading as of 2026-09-16 10:24:00, down 0,53% ($0,00) from the previous close of $0,57
Pre-market trading shows how investors are pricing GUTS before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Fractyl Health, Inc. (GUTS) moved from $0,70 to $0,56, representing a decline of 19,32% ($0,13).
The stock traded between $0,56 and $0,72 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,12 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8,9%
GUTS is currently trading at $0,56, placing it 8,9% of the way from its 52-week low of $0,38 to its 52-week high of $2,45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fractyl Health, Inc. (GUTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.